Neurocrine biosciences announces publication on traditional glucocorticoid treatment in classic congenital adrenal hyperplasia in expert review of endocrinology & metabolism

Narrative review assesses current treatment challenges and the evolving classic congenital adrenal hyperplasia (cah) therapeutic landscape non-glucocorticoid (gc) mechanisms for treatment of cah could enable control of excess acth and androgens without the need for high-dose gcs, reducing related complications over a lifetime san diego , jan. 8, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced publication of a narrative review discussing the challenges of traditional treatment of classic congenital adrenal hyperplasia (cah) with glucocorticoids (gcs) alone and the potential benefits of introducing novel non-gc mechanisms for treating the condition that may enable lower, more physiologic gc dosing. the publication appears in expert review of endocrinology & metabolism.
NBIX Ratings Summary
NBIX Quant Ranking